References
- Hale G, Bright S, Chumbley G, Hoang T, Metcalf D, Munro A J, et al. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood 1983; 62: 873–882
- Mavromatis B, Cheson B D. Monoclonal antibody therapy of chronic lymphocytic leukemia. J Clin Oncol 2003; 21: 1874–1881
- Rodig S J, Abramson J S, Pinkus G S, Treon S P, Dorfman D M, Dong H Y, et al. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). Clin Cancer Res 2006; 12: 7174–7179
- Zent C S, Chen J B, Kurten R C, Kaushal G P, Lacy H M, Schichman S A. Alemtuzumab (CAMPATH 1H) does not kill chronic lymphocytic leukemia cells in serum free medium. Leuk Res 2004; 28: 495–507
- Lundin J, Kimby E, Bjorkholm M, Broliden P A, Celsing F, Hjalmar V, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002; 100: 768–773
- Hui D, Lam W, Toze C, Delorme M, Noble M, Klimo P, Sutherland J, Gill K, Connors J, Sehn L. Alemtuzumab in clinical practice: A British Columbia experience. Leuk Lymphoma 2008; 49: 218–226
- Fiegl M, Falkner A, Hopfinger G, Brugger S, Zabernigg A, Bauer F, et al. Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria. Cancer 2006; 107: 2408–2416